Kirkland & Ellis acted because the lead counsel to a consortium of buyers within the proposed $4.76 billion take-private of China Biologic Products Holdings, Inc. (NASDAQ: CBPO), a plasma-based biopharmaceutical business. The investor consortium comprised of Centurium Capital, CITIC Capital, Mr. Marc Chan, Hillhouse Capital, Temasek Holdings, and Mr. Joseph Chow, CEO and chairman of the board of administrators of CBPO and their respective associates. The transaction was signed on November 19, 2020.
The Kirkland workforce was led by transactional companions Gary Li, Xiaoxi Lin, Sarkis Jebejian, Julia Yu, James Hu and Pierre-Luc Arsenault. The workforce additionally included debt finance accomplice Jacqueline Zheng, funding funds companions Justin Dolling and Jennifer Feng, capital markets companions Joshua Korff and Ben James, litigation accomplice Matthew Solum, tax companions Michael Beinus and Devin Heckman, and authorities and inside investigations accomplice Cori Lable. Transactional accomplice Joey Chau suggested on the Hong Kong regulatory facet of the transaction.